Cyclerion shares rise 10.91% after-hours on strategic agreement with Medsteer and progress toward Phase 2 study for CYC-126 in treatment-resistant depression.

Cyclerion Therapeutics (CYCN) surged 10.91% in after-hours trading following a strategic agreement with Medsteer and progress toward initiating a Phase 2 proof-of-concept study for CYC-126 in treatment-resistant depression. The partnership and clinical advancement highlight potential therapeutic progress in neuropsychiatric disorders, aligning with Cyclerion’s repositioning as a neuropsychiatric-focused company. The after-hours rally suggests investor optimism over the collaboration’s implications for drug development and commercialization prospects.